Table 1.
Therapeutics analyzed for HCP content organized by the Year of FDA approval
| Drug trade name |
First US approval year |
International nonproprietary name |
IgG subclass |
Class |
Company |
| Rituxan | 1997 | Rituximab | IgG1 | mAb | Genentech/Biogen |
| Enbrel | 1998 | Etanercept | IgG1 | Fusion | Amgen |
| Herceptin | 1998 | Trastuzumab | IgG1 | mAb | Genentech |
| Humira | 2002 | Adalimumab | IgG1 | mAb | AbbVie |
| Xolair | 2003 | Omalizumab | IgG1 | mAb | Genentech/Novartis |
| Orencia | 2005 | Abatacept | CTLA4-IgG1 | Fusion | BMS |
| Vectibex | 2006 | Pamitumumab | IgG2 | mAb | Amgen |
| Actemra | 2010 | Tocilizumab | IgG1 | mAb | Genentech |
| Xgeva | 2010 | Denosumab | IgG2 | mAb | Amgen |
| Yervoy | 2011 | Ipilimumab | IgG1 | mAb | BMS |
| Perjeta | 2012 | Pertuzumab | IgG1 | mAb | Genentech |
| Keytruda | 2014 | Pembrolizumab | IgG4 | mAb | Merck |
| Opdivo | 2014 | Nivolumab | IgG4 | mAb | BMS |
| Cosentyx | 2015 | Secukinumab | IgG1 | mAb | Novartis |
| Darzalex | 2015 | Daratumumab | IgG1 | mAb | Janssen |
| Nucala | 2015 | Mepolizumab | IgG1 | mAb | GSK |
| Repatha | 2015 | Evolocumab | IgG2 | mAb | Amgen |
| Praluent | 2015 | Alirocumab | IgG1 | mAb | Regeneron |
| Tecentriq | 2016 | Atezolizumab | IgG1 | mAb | Genentech |
| Fasenra | 2017 | Benralizumab | IgG1 | mAb | AstraZeneca |
| Hemlibra | 2017 | Emicizumab-kxwh | IgG1 | Bispecific | Genentech |
| Imfinzi | 2017 | Durvalumab | IgG1 | mAb | AstraZeneca |
| Imraldi | 2017 | Adalimumab-xxxx | IgG1 | mAb | Samsung Bioepis |
| Dupixent | 2017 | Dupilumab | IgG4 | mAb | Regeneron |
| Kevzara | 2017 | Sarilumab | IgG1 | mAb | Regeneron |
| Hulio | 2018 | Adalimumab-fkjp | IgG1 | mAb | Mylan |
| Libtayo | 2018 | Cemiplimab-rwlc | IgG4 | mAb | Regeneron |
| Kanjinti | 2019 | Trastuzumab-anns | IgG1 | mAb | Amgen |
| Trazimera | 2019 | Trastuzumab-qyyp | IgG1 | mAb | Pfizer |